Patrick Peterson

523 total citations
24 papers, 328 citations indexed

About

Patrick Peterson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Patrick Peterson has authored 24 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Patrick Peterson's work include Sarcoma Diagnosis and Treatment (5 papers), CAR-T cell therapy research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Patrick Peterson is often cited by papers focused on Sarcoma Diagnosis and Treatment (5 papers), CAR-T cell therapy research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Patrick Peterson collaborates with scholars based in United States, Spain and United Kingdom. Patrick Peterson's co-authors include Douglas J. Lanska, Allen S. Melemed, Aman U. Buzdar, Astra M. Liepa, William J. John, Eric P. Winer, Joyce O’Shaughnessy, John Pippen, Clifford A. Hudis and Daniel J. Booser and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Stroke.

In The Last Decade

Patrick Peterson

23 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Peterson United States 10 149 98 78 64 46 24 328
Kimberly A. Herget United States 11 128 0.9× 31 0.3× 54 0.7× 33 0.5× 40 0.9× 23 293
Chenjie Zeng United States 7 156 1.0× 51 0.5× 87 1.1× 46 0.7× 32 0.7× 12 369
Deanna Cross United States 10 74 0.5× 77 0.8× 29 0.4× 48 0.8× 23 0.5× 24 288
Gilberto Uemura Brazil 10 230 1.5× 53 0.5× 38 0.5× 92 1.4× 60 1.3× 31 474
William Aiken Jamaica 14 151 1.0× 75 0.8× 261 3.3× 90 1.4× 42 0.9× 42 537
Robin Schaffar Switzerland 10 196 1.3× 61 0.6× 126 1.6× 33 0.5× 28 0.6× 19 338
Dante diTommaso United States 6 153 1.0× 46 0.5× 330 4.2× 142 2.2× 33 0.7× 7 530
Anna Plym Sweden 12 124 0.8× 40 0.4× 141 1.8× 53 0.8× 39 0.8× 28 330
En Cheng United States 11 222 1.5× 28 0.3× 71 0.9× 43 0.7× 35 0.8× 30 420
Nur Zeinomar United States 11 211 1.4× 96 1.0× 25 0.3× 76 1.2× 45 1.0× 29 439

Countries citing papers authored by Patrick Peterson

Since Specialization
Citations

This map shows the geographic impact of Patrick Peterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Peterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Peterson more than expected).

Fields of papers citing papers by Patrick Peterson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Peterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Peterson. The network helps show where Patrick Peterson may publish in the future.

Co-authorship network of co-authors of Patrick Peterson

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Peterson. A scholar is included among the top collaborators of Patrick Peterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Peterson. Patrick Peterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Schöffski, Patrick, Rastislav Bahleda, Andrew J. Wagner, et al.. (2023). Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 29(17). 3320–3328. 9 indexed citations
3.
Attia, Steven, Víctor M. Villalobos, Nadia Hindi, et al.. (2023). Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers. 15(19). 4871–4871. 1 indexed citations
4.
Schöffski, Patrick, Rastilav Bahleda, Andrew J. Wagner, et al.. (2021). 154P Results of an open-label, phase Ia/Ib study of olaratumab plus pembrolizumab in patients with unresectable, locally advanced or metastatic soft tissue sarcoma. Annals of Oncology. 32. S1447–S1447. 1 indexed citations
5.
Jones, Robin L., Andrew J. Wagner, Akira Kawai, et al.. (2021). Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clinical Cancer Research. 27(14). 3861–3866. 31 indexed citations
6.
Hess, Lisa M., et al.. (2021). Health and resource burden of a cancer diagnosis on the caregiver: an analysis of administrative claims data. BMC Health Services Research. 21(1). 894–894. 3 indexed citations
7.
8.
9.
Jones, Robin L., Gary Mo, John R. Baldwin, et al.. (2018). Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. Cancer Chemotherapy and Pharmacology. 83(1). 191–199. 9 indexed citations
10.
Smyth, Emily Nash, Wei Shen, Lee Bowman, et al.. (2016). Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health and Quality of Life Outcomes. 14(1). 52–52. 29 indexed citations
11.
12.
Peterson, Patrick, Kevin Carroll, Christy Chuang‐Stein, et al.. (2010). PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment From a Randomized, Active-Controlled Trial. Statistics in Biopharmaceutical Research. 2(4). 522–531. 13 indexed citations
13.
Alexander, Nicholas, et al.. (2007). Defense Contracting: Improved Insight and Controls Needed over DOD's Time-and-Materials Contracts. Defense Technical Information Center (DTIC). 1 indexed citations
14.
Melemed, Allen S., et al.. (2007). Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 25(31). 4967–4973. 57 indexed citations
15.
Ritch, Paul S., Charles M. Rudin, Jacob D. Bitran, et al.. (2006). Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 52(2). 173–180. 27 indexed citations
16.
Buzdar, Aman U., Joyce O’Shaughnessy, Daniel J. Booser, et al.. (2003). Phase II, Randomized, Double-Blind Study of Two Dose Levels of Arzoxifene in Patients With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 21(6). 1007–1014. 51 indexed citations
17.
Lanska, Douglas J. & Patrick Peterson. (1996). Comparison of Additive and Multiplicative Models of Regional Variation in the Decline of Stroke Mortality in the United States. Stroke. 27(6). 1055–1059. 4 indexed citations
18.
Lanska, Douglas J. & Patrick Peterson. (1995). Geographic Variation in Reporting of Stroke Deaths to Underlying or Contributing Causes in the United States. Stroke. 26(11). 1999–2003. 7 indexed citations
19.
Lanska, Douglas J. & Patrick Peterson. (1995). Effects of Interstate Migration on the Geographic Distribution of Stroke Mortality in the United States. Stroke. 26(4). 554–561. 18 indexed citations
20.
Yung, W.K. Alfred, et al.. (1994). A PHASE II STUDY OF riFN–β+/- cRA IN RECURRENT GLIOMAS. Journal of Immunotherapy. 16(3). 246–246. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimberly A. Herget Breakdown of academic impact, for papers by Chenjie Zeng Breakdown of academic impact, for papers by Deanna Cross Breakdown of academic impact, for papers by Gilberto Uemura Breakdown of academic impact, for papers by William Aiken Breakdown of academic impact, for papers by Robin Schaffar Breakdown of academic impact, for papers by Dante diTommaso Breakdown of academic impact, for papers by Anna Plym Breakdown of academic impact, for papers by En Cheng Breakdown of academic impact, for papers by Nur Zeinomar
Rankless by CCL
2026